Skip to content

WBA scales back stake in China joint venture

Walgreens Boots Alliance (WBA) plans to reduce its interest in Guangzhou Pharmaceuticals Corp., a pharmaceutical wholesale joint venture in China. WBA said Friday that, under the agreement, it will sell a 30% stake in Guangzhou Pharmaceuticals to Guangzhou Baiyunshan Pharmaceutical Holdings.

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) plans to reduce its interest in Guangzhou Pharmaceuticals Corp., a pharmaceutical wholesale joint venture in China.

WBA said Friday that, under the agreement, it will sell a 30% stake in Guangzhou Pharmaceuticals to Guangzhou Baiyunshan Pharmaceutical Holdings.

After the proposed sale, which is pending regulatory approval and other customary closing conditions, Guangzhou Baiyunshan would hold 80% interest in Guangzhou Pharmaceuticals, while WBA would own a 20% interest. WBA said it will continue to account for its remaining stake as an equity method investment.

Earlier this month, WBA unveiled a $416 million deal to acquire a 40% stake in Sinopharm Holding GuoDa Drug Store Co. GuoDa is China’s largest retail pharmacy operator and a subsidiary of state-owned Sinopharm, the nation’s biggest pharmaceutical company.

Latest

H-E-B embodies purposefulness

H-E-B embodies purposefulness

During remarks delivered at last month’s FMI Midwinter Executive Conference, Boyan, who is also the association’s chairman, spoke about what motivates the company.

The K-shaped economy’s hidden truths

The K-shaped economy’s hidden truths

New research from the Kearney Consumer Institute uncovers some hidden aspects of the trend, which, of course, has serious implications for both mass market retailers and consumer packaged goods companies.